Two eculizumab biosimilars bring those authorized in Europe to 76

Industry news

June 6th, 2023Industry News

In April and May, the European Commission authorized two biosimilars of eculizumab, the medication indicated for the treatment of adults and children with paroxysmal nocturnal hemoglobinuria.

READ MORE

recently published

Post thumb
Informative breakfasts "Study on the market of biosimilar medicines in the National Health System in Spain"
March 18 2024
Post thumb
Horizon scanning
Jan 31 2024
Post thumb
Early Treatment: the role of biosimilars
18 2023 December
Post thumb
Study on the market for biosimilar medicines in the National Health System in Spain 2016-2022
18 2023 December

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE